Elevated serum phosphate concentration may be associated with an increased risk for major adverse limb events in patients undergoing hemodialysis.
A study of stable dialysis patients receiving sucroferric oxyhydroxide found no significant changes in hemoglobin, ferritin level, and transferrin saturation.
Achieving serum phosphate levels of 3.5 to 4.5 mg/dL vs 5.0 to 6.0 mg/dL in patients on hemodialysis was associated with less coronary artery calcification, study findings suggest.
In a study of hospitalized patients, increased serum phosphate levels significant increased the risk of acute kidney injury, end-stage renal disease, and death.
In a study of hemodialysis patients, PAD risk increased nonlinearly with serum phosphate level.
By blocking paracellular phosphate transport, tenapanor added to phosphate binders may improve the hyperphosphatemia management in patients on maintenance dialysis, a study found.
In a study, elevated FGF23 was associated with increased risks of major adverse cardiovascular events and mortality in type 2 diabetes patients with normal or mildly impaired kidney function.
If confirmed, findings from 2 new studies would have important clinical implications for phosphate intake in the general population.
In a 2-day dietary intervention study, very-low-phosphate and low-phosphate diets decreased fibroblast growth factor 23 levels to a similar degree in patients on hemodialysis, but the very-low-phosphate diets results in greater lowering of phosphorus levels.
Prescriptions of drugs to treat chronic kidney disease-mineral bone disorders varies widely by country, but it is generally low, a study found.